<DOC>
	<DOCNO>NCT02895854</DOCNO>
	<brief_summary>The aim trial find difference profile acute late adverse effect among men low intermediate risk prostate cancer treat either low dose-rate brachytherapy hypofractionated external radiotherapy ( CyberKnife ) . Also prostate specific antigen ( PSA ) responses cost utility treatment analyse .</brief_summary>
	<brief_title>LDR Brachytherapy Versus SBRT Low Intermediate Risk Prostate Cancer Patients</brief_title>
	<detailed_description>Prostate cancer ( PC ) common solid malignancy among men Western world . The classification low , intermediate high risk group determine PSA , Gleason score clinical TNM status moment diagnosis . There several treatment option available patient low intermediate risk PC generally prognosis good . The men live long radical treatment live possible adverse effect cause treatment . In prospective , randomise clinical trial compare two radiotherapy modality find difference acute late adverse effect among men treat either low dose-rate ( LDR ) brachytherapy hypofractionated external radiotherapy . Also PSA-responses cost utility analyse . The number patient recruit study 60 patient randomise 1:1 treatment arm .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>biopsy proven adenocarcinoma prostate Gleason score ≤ 3+4 clinical radiological TNM T1c2c , N0X , M0X , PSA ≤ 20ng/ml WHO 02 low intermediate risk prostate cancer accord National Comprehensive Cancer Network ( NCCN ) classification clinical TNM ≥ T3 Gleason score ≥ 4+3 high risk prostate cancer accord NCCN classification history cancer ( PC ) past 5 year ( exclude basalioma squamocellular carcinoma skin ) previous pelvic radiotherapy previous active treatment prostate cancer ( active surveillance allow ) bilateral hip prothesis implant impedes pelvic TT MRI image clopidogrel medication poor cooperation life expectancy &lt; 5 yr</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Low risk prostate cancer</keyword>
	<keyword>Intermediate risk prostate cancer</keyword>
	<keyword>Low dose-rate brachytherapy</keyword>
	<keyword>Hypofractionated</keyword>
	<keyword>Robotic external beam radiation</keyword>
	<keyword>Quality life</keyword>
</DOC>